CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED SUPPLEMENTAL AGREEMENT FOR NHCMSupplemental Agreement • November 13th, 2023 • LianBio • Pharmaceutical preparations • New York
THIS SUPPLEMENTAL AGREEMENT FOR NHCM (this “nHCM Supplemental Agreement”), dated as of August 11, 2023 (the “nHCM Supplemental Agreement Effective Date”), is made by and between MyoKardia, Inc., a corporation organized and existing under the laws of the State of Delaware, having its place of business at 1000 Sierra Point Parkway, Brisbane, California 94005 United States (“Company”), on the one hand, and LianBio, an exempted company organized under the laws of the Cayman Islands (“LianBio”), LianBio Licensing, LLC, a limited liability company organized and existing under the laws of the State of Delaware, having its place of business at 103 Carnegie Center Drive Suite 215, Princeton, NJ 08540 (“LianBio Licensing”), and Lian Cardiovascular Limited, a private company limited by shares organized under the laws of Hong Kong (“Lian Cardiovascular HK”), and Shanghai LianBio Development Co., Ltd., a limited liability company organized and existing under the laws of the PRC (“Local Regulatory A
